Dr Reddy's Says US FDA Grants Tentative Approval For Twice-Yearly Injectable Lenacapavir

What happened

Dr. Reddy’s Laboratories said the U.S. FDA granted tentative approval for its twice-yearly injectable lenacapavir. The company said it will be available at $40 per person per year across 120 countries covered by Gilead’s voluntary licence, with first supplies expected before the end of 2026 and broader availability in 2027.

Confirmed

Global impact / market context

Tentative approval is a regulatory step, but the article does not state that final approval or launch has occurred. If supplies begin as planned, sales could add revenue for Dr. Reddy’s, while the $40 annual price and licence-covered reach shape the potential scale of that opportunity.

Analyst inference

The announcement combines a U.S. regulatory milestone with a stated low annual price and access across 120 licence-covered countries. The gap until expected supplies before the end of 2026 means investors have timing and execution questions before any commercial contribution is confirmed.

Analyst inference

What to watch

1. Whether the FDA grants final approval, since the article reports only tentative approval and does not establish that the injectable can yet be marketed. Analyst inference
2. Whether Dr. Reddy’s meets its stated expectation for first supplies before the end of 2026 and broader availability across eligible countries in 2027. Analyst inference
3. Whether the $40-per-person annual price applies as stated across the 120 countries covered by Gilead’s voluntary licence, as wider access could affect sales volume. Analyst inference

Evidence

• Original source link unavailable